Groundbreaking research suggests that retatrutide, a dual-action medication, could transform the treatment of obesity . Differing from many current weight management solutions, retatrutide operates as both a GLP-1 receiver and a GIP receiver , targeting multiple factors involved in appetite regulation and glucose control . Initial clinical trials